Patients with multiple myeloma who are resistant to bortezomib should stop using it and replace it with other drugs, such as ibrutinib, immunomodulators (thalidomide, etc.) in combination therapy, and also hematopoietic stem cell transplantation and other treatments. 1. Irutinib: it is a small molecule tyrosine kinase inhibitor, which can inhibit the survival and proliferation of malignant B cells, and has therapeutic value for bortezomib-resistant myeloma patients. 2. Immunomodulator combination therapy: commonly used treatment options include immunomodulators + glucocorticoids, immunomodulators + traditional chemotherapeutic drugs + glucocorticoids. Commonly used immunomodulators include thalidomide, lenalidomide, pomalidomide and so on. 3. Hematopoietic stem cell transplantation: autologous hematopoietic stem cell transplantation can be tried after detailed evaluation, and allogeneic hematopoietic stem cell transplantation can be considered as appropriate for some young high-risk patients. When myeloma patients are resistant to bortezomib, it is recommended to go to the hospital in time for early and regular treatment. All of the above medications should be used under the guidance of a doctor, avoid self-medication.